Study design considerations to assess the impact of potential drug-drug interactions in first-in-human studies in oncology drug development
Clin Transl Sci
.
2023 May;16(5):719-722.
doi: 10.1111/cts.13496.
Epub 2023 Feb 23.
Authors
Sriram Subramaniam
1
,
Stacy S Shord
1
,
Ruby Leong
1
,
Kelly Norsworthy
1
,
Atiqur Rahman
1
,
Brian Booth
1
,
Olanrewaju Okusanya
1
Affiliation
1
US Food and Drug Administration, Silver Spring, Maryland, USA.
PMID:
36823411
PMCID:
PMC10176012
DOI:
10.1111/cts.13496
No abstract available
MeSH terms
Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Drug Development
Drug Interactions
Humans
Medical Oncology
Neoplasms* / drug therapy
Research Design
Substances
Antineoplastic Agents